Repligen Corporation
Repligen Corporation (RGEN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RGEN · as of Sep 30, 2025
Ownership Breakdown
476
Institutional Holders
▲ 17 vs Q2
$8.00B
Total Inst. Value
▲ $776.52M vs Q2
56.41M
Shares Outstanding
freeFloat 94.60%
60.21M
13F Shares Held
▲ 1.39M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RGEN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 6.14M | 10.93% | 10.93% | $820.70B | Nov 12, 2025 | ▲ 61.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 5.04M | 8.98% | 8.98% | $674.26B | Nov 7, 2025 | ▼ 33.0K |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 3.51M | 6.24% | 6.24% | $468.83B | Nov 14, 2025 | ▼ 3.10M |
UNITED CAPITAL FINANCIAL ADVISERS, LLC biological products, (no diagnostic substances) | 2.76M | 4.91% | 4.91% | $368.39B | Nov 14, 2025 | NEW |
FMR LLC biological products, (no diagnostic substances) | 2.69M | 4.79% | 4.79% | $359.73B | Nov 13, 2025 | ▲ 1.08M |
STATE STREET CORP biological products, (no diagnostic substances) | 1.80M | 3.21% | 3.21% | $240.81B | Nov 14, 2025 | ▲ 178.9K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 1.68M | 3.00% | 3.00% | $225.20B | Nov 14, 2025 | ▲ 621.7K |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.44M | 2.56% | 2.56% | $192.58B | Nov 14, 2025 | ▼ 472.5K |
HOLOCENE ADVISORS, LP biological products, (no diagnostic substances) | 1.38M | 2.45% | 2.45% | $184.08B | Nov 14, 2025 | ▲ 440.3K |
CHAMPLAIN INVESTMENT PARTNERS, LLC biological products, (no diagnostic substances) | 1.34M | 2.38% | 2.38% | $179.02B | Nov 12, 2025 | ▼ 61.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+4.86M shares4
New Positions
first time holders17
Decreased
−4.91M shares0
Sold Out
fully exitedNet shares change (top 50)
50.7K
+4.86M / −4.91M
Net new holders
+16
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RGEN insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
2
Sell transactions
1.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Madaus Martin D director | May 14, 2026 | Award | 995 | — | — | 6.6K | Form 4 ↗ |
Madaus Martin D director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
Konstantinov Konstantin director | May 14, 2026 | Award | 995 | — | — | 3.9K | Form 4 ↗ |
Konstantinov Konstantin director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
EGLINTON MANNER CARRIE director | May 14, 2026 | Award | 995 | — | — | 5.5K | Form 4 ↗ |
Mhatre Rohin director | May 14, 2026 | Award | 995 | — | — | 5.0K | Form 4 ↗ |
Mhatre Rohin director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
EGLINTON MANNER CARRIE director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
Pax Margaret director | May 14, 2026 | Award | 995 | — | — | 3.0K | Form 4 ↗ |
Pax Margaret director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Repligen Corporation (RGEN) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 5.40%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Repligen Corporation is BLACKROCK, INC., holding approximately 6.14 million shares — equal to 10.93% of outstanding shares — as of September 30, 2025.
A total of 476 institutional investors currently hold RGEN stock, with a combined institutional value of approximately $8.00 billion as of the most recent 13F filing period.
Frequently asked questions
RGEN ownershipRepligen Corporation (RGEN) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 10.93% stake. Company insiders hold 5.40%. Data sourced from SEC Form 13F as of September 30, 2025.